Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

TolerRx brings in $35.6mm with its latest venture round

Executive Summary

TolerRx (immune system therapeutics) has raised $35.6mm with its latest venture round. New investor FrontPoint Partners led the round and was joined by other new backers Mesirow Financial, Swiss Re, QVT Fund, IBT Management, Brookstone Capital, and the Juvenile Diabetes Research Foundation. Returning participants included Skyline Ventures, Bear Stearns, Sprout Group, Rho Ventures, Artal Services, and HealthCare Ventures. TolerRx will use the funds to continue developing the anti-CD3 monoclonal antibody TRX4, its lead candidate that is in Phase II for Type I diabetes and Phase I for psoriasis.
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Large Molecule
      • Antibodies
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies